Nama's AI scorecard currently rates Nektar Therapeutics Sell (3.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does NKTR report earnings?

Nektar Therapeutics's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$2.07.

What is the NKTR price target?

The median analyst price target from 12 analysts is $150.00, with a range of $50.00 – $192.00.

Is NKTR Shariah compliant?

Nama's AAOIFI-style screen reads Nektar Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Nektar Therapeutics (NKTR)

Healthcare · Biotechnology · NASDAQ

Nektar Therapeutics (NKTR) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.27B and a free-cash-flow yield of -33.2%. Over the most recent reported fiscal year, revenue declined 43.9%. Nama's AI scorecard rates it Sell, 3.7 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.7/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -27.0% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-84.4%

How far the last close sits under the highest price of the past five years.

Market cap	$1.27B
Trailing P/E	—
Price / book	1.4
Price / sales	23.3
FCF yield	-33.2%
Dividend yield	—
Gross margin	101.2%
Operating margin	-239.3%
Net margin	-287.8%
Revenue growth (YoY)	-43.9%
Revenue growth (3-yr annual)	-15.7%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

NKTR earnings

Next report: Nov 12, 2026 (Q3 2026, EPS estimate -$2.07). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 13, 2026	-$1.21	-$2.04	+40.7%	$10.13M
Q1 2026	May 7, 2026	-$1.78	-$1.48	-20.3%	$10.86M
Q4 2025	Mar 12, 2026	-$1.29	-$3.49	+63.0%	$21.81M
Q3 2025	Nov 6, 2025	-$1.87	-$2.79	+33.0%	$11.79M

NKTR analyst price target

Median target $150.00 from 12 analysts, ranging $50.00 – $192.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live NKTR data on Nama Insights →

NKTR FAQ

Is NKTR a buy?: Nama's AI scorecard currently rates Nektar Therapeutics Sell (3.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does NKTR report earnings?: Nektar Therapeutics's next scheduled report is on Nov 12, 2026. Analysts expect EPS of -$2.07.
What is the NKTR price target?: The median analyst price target from 12 analysts is $150.00, with a range of $50.00 – $192.00.
Is NKTR Shariah compliant?: Nama's AAOIFI-style screen reads Nektar Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.